BioNTech SE: BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO

Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive interim data presented at AACR in AprilStrongest

Related Keywords

Germany ,Erlangen ,Bayern ,United States ,American ,Sylke Maas ,Andreas Mackensen ,Fosun Pharma ,Genentech ,Association For Cancer Immunotherapy ,University Hospital Erlangen ,Pfizer ,American Association For Cancer Research ,Vp Corporate Communications ,Roche Group ,European Medicines Agency ,European Society For Medical Oncology ,Priority Medicines ,European Society ,Medical Oncology ,European Medicines Agencyparticularly ,American Association ,Cancer Research ,Chief Medical Officer ,New Technologies ,Private Securities Litigation Reform Act ,Quarterly Report ,Biontech ,Presents ,Ncouraging ,Hase ,Follow ,Data ,Candidate ,Bnt211 ,Yard ,Treat ,Olid ,Rumors ,Osmo ,